| 1. |
HIV preventive efforts missing their mark in worst hit countries |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 2. |
Ramipril: clinical, economic advantages in diabetes, stable angina |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 3-4
&NA;,
Preview
|
|
摘要:
It is estimated that there are currently about 17.2 million individuals with diabetes mellitus in the US, of which type 2 diabetes accounts for 90−95% of cases. Individuals with diabetes are at high risk of developing hypertension, heart disease, stroke, myocardial infarction (MI) and other complications. Furthermore, the risk of cardiovascular death is two- to three-fold higher among women with diabetes versus those without diabetes, and three- to four-fold higher among men with versus without diabetes. Consequently, reducing the risk of such events, and the related costs, among individuals with diabetes is a pertinent issue for healthcare payers in the US. Ramipril is one of the most potent long-acting ACE-inhibitors available, and has been shown to be effective for treating all grades of hypertension and heart failure. The cost effectiveness of ramipril treatment among patients with diabetes is therefore of great interest to healthcare professionals in the US. Similarly, the risk of cardiovascular (CV) events and death is high among patients who undergo percutaneous coronary intervention (PCI) for stable angina pectoris. The benefits of ramipril therapy among these patients have been shown in large clinical trials, and the favourable cost effectiveness of such therapy will enhance its worth among certain patient populations. These issues were examined in two studies presented at the 52nd Annual Scientific Session of the American College of Cardiology [Chicago, US; March/April 2003]
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 3. |
An advisory statement on antibacterial prophylaxis in urological patients with total joint replacements has been released |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 4. |
Penicillin resistance increases cost of treating pneumococcal infections |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 5. |
Diabetic complications: substantial costs in the US |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 6. |
Asthma controller use not improved with scheduled follow-up |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 7. |
Drug safety improved with pharmaceutical case management |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 8. |
CV therapy use less than expected for diabetes mellitus in Ireland |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 9. |
IBS: bloated financial burden for US employers |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
| 10. |
Nurse prescribers in the UK will be allowed to prescribe certain medications off-label for use in palliative care |
| |
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 413,
2003,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2003
数据来源: ADIS
|
首页
